In the last trading session, 1.33 million Elevation Oncology Inc (NASDAQ:ELEV) shares changed hands as the company’s beta touched 1.28. With the company’s per share price at $0.57 changed hands at -$0.01 or -1.12% during last session, the market valuation stood at $31.43M. ELEV’s last price was a discount, traded about -922.81% off its 52-week high of $5.83. The share price had its 52-week low at $0.44, which suggests the last value was 22.81% up since then. When we look at Elevation Oncology Inc’s average trading volume, we note the 10-day average is 1.18 million shares, with the 3-month average coming to 791.17K.
Analysts gave the Elevation Oncology Inc (ELEV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ELEV as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Elevation Oncology Inc’s EPS for the current quarter is expected to be -0.21.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Instantly ELEV was in red as seen at the end of in last trading. With action -10.39%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 6.80%, with the 5-day performance at -10.39% in the red. However, in the 30-day time frame, Elevation Oncology Inc (NASDAQ:ELEV) is -5.24% down. Looking at the short shares, we see there were 6.13 million shares sold at short interest cover period of 9.52 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 93.67% from its current market value. According to analyst projections, ELEV’s forecast low is 8 with 10 as the target high. To hit the forecast high, the stock’s price needs a -1654.39% plunge from its current level, while the stock would need to soar -1303.51% for it to hit the projected low.
Elevation Oncology Inc (ELEV) estimates and forecasts
Data shows that the Elevation Oncology Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -76.20% over the past 6 months, a 36.57% in annual growth rate that is considerably higher than the industry average of 17.20%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -52.56%. The 2024 estimates are for Elevation Oncology Inc earnings to increase by 36.19%.
ELEV Dividends
Elevation Oncology Inc is expected to release its next quarterly earnings report in January.
Elevation Oncology Inc (NASDAQ:ELEV)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.27% of Elevation Oncology Inc shares while 83.85% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.08%. There are 83.85% institutions holding the Elevation Oncology Inc stock share, with LOGOS GLOBAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 6.5234% of the shares, roughly 3.85 million ELEV shares worth $10.39 million.
FARALLON CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 6.0971% or 3.6 million shares worth $9.72 million as of 2024-06-30.
